Table 4.

Clinical variables, immune molecules and antimicrobial activity in cervicovaginal lavage following categorization of participants by number of different types of HPV detected.

Variable	0 HPV types (n=32)	1 HPV types (n=35)	2–3 HPV types (n=35)	≥4 HPV types (n=26)	p-values
Pap result, n (%)					0.002
Normal	24 (75%)	24 (68.6%)	19 (54.3%)	3 (23.1%)
ACUS/LGSIL	6 (18.8%)	9 (25.7%)	13 (37.1%)	17 (65.4%)
HGSIL	2 (6.2%)	2 (5.7%)	3 (8.6%)	3 (11.5%)
CD4 cells/mm3 median [IQR]	520 [383.5 – 672]	458 [315 – 573]	473 [349 – 737]	310.5 [209 – 513]	0.02
* Plasma viral load, n (%)					0.01
≤ 20 copies/ml	23 (71.9%)	21 (61.8%)	17 (50%)	6 (23.1%)
< 15,800 (median)	7 (21.9%)	11 (32.3%)	12 (35.3%)	14 (53.8%)
≥ 15,800 (median)	2 (6.2%)	2 (5.9%)	5 (14.7%)	6 (23.1%)
IL-1α (pg/mL)	64 [24.1–116.1]	61.2 [19.0 – 111.7]	68.4 [28.4 – 303.8]	218.1 [68.8 – 671.7]	0.01
IL-8 (log10 pg/mL)	2.43 ± 0.85	2.50 ± 0.72	2.29 ± 0.67	2.59 ± 0.82	0.47
IFN-γ (pg/mL),	0.77 [0.32–1.07]	0.51 [0.26–0.90]	0.64 [0.30 – 1.07]	0.78 [0.32–3.66]	0.18
SLPI (pg/mL)	102950 [15225–243259]	43399 [3750–163226]	33255 [3750–207490]	64671 [10659–221049]	0.51
HBD-2 (pg/mL)	349.2 [142–758.8]	245.7 [47.9–1237.6]	567.8 [269.6–2226]	1624.8 [166.2–3187.5]	0.02
HNP1–3 (log10pg/mL)	5.15 ± 0.49	5.07 ± 0.66	4.96 ± 0.65	4.78 ± 0.67	0.14
E. coli inhibition (%)	22 [7 – 34.5]	13 [1.5 – 31]	8 [−5 – 28]	12.5 [−9 – 32]	0.25
HSV inhibition (%)	23 [8.7–48]	15 [4.2 – 47]	22 [4 – 45]	14.5 [0 – 36]	0.49
HIVBaL inhibition (%)	57 [29–91]	58.8 [8.5 – 86.5]	59 [15 – 87]	47.7 [−37.5 – 61.5]	0.50
HIVIIIb inhibition (%)	87 [64–97]	91.7 [74 – 99]	81.9 [61 – 96.3]	83.3 [44 – 96.7]	0.31

^*PVL was dichotomized at the median of 15,800 copies/ml.